Financial Performance - Normalised revenue increased by 82.3% to $6.0085 billion[12, 21], and normalised EBIT increased by 41.4% to $834.5 million[11, 12, 21, 74] - Statutory NPAT increased by 40% to $579.1 million[12] - Pro-forma revenue reached $9.6 billion[13, 27], and pro-forma EBIT was $903.4 million[13, 27] - Net debt to normalised EBITDA ratio is 0.85x[14, 18, 37] Growth and Expansion - Chemist Warehouse (CW) retail network sales increased by 14% to $10.3 billion[10] - Australian CW franchise stores experienced 11.3% like-for-like sales growth[10, 30] - The company has expanded to 674 Chemist Warehouse stores globally[10, 46, 74] Synergies and Efficiencies - Synergies target upgraded to $100 million per annum by year four[10, 56, 58] - Distribution Centre (DC) volumes increased by 29% to over 532 million units[10, 57] - Logistics costs decreased by 11% per unit[10] Product Strategy - Over 20% growth in FY25 sales of own and exclusive label products[10, 54] - Launched Wagner generic medicines in November 2024[10, 54]